Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis

标题
Lenvatinib Versus Sorafenib as First‐Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost–Utility Analysis
作者
关键词
-
出版物
ONCOLOGIST
Volume -, Issue -, Pages theoncologist.2019-0501
出版商
Alphamed Press
发表日期
2019-11-21
DOI
10.1634/theoncologist.2019-0501

向作者/读者发起求助以获取更多资源

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started